LRP1-Dependent Tau Uptake Disruption

Target: LRP1 Composite Score: 0.437 Price: $0.45▼1.8% Citation Quality: Pending Alzheimer's Disease Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🧠 Neurodegeneration
🏆 ChallengeSolve: Sleep disruption as cause and consequence of neurodegeneration$93K bounty →
✓ All Quality Gates Passed
Quality Report Card click to collapse
C
Composite: 0.437
Top 68% of 513 hypotheses
T3 Provisional
Single-source or model-inferred
Needs composite score ≥0.60 (current: 0.44) for Supported
C+ Mech. Plausibility 15% 0.51 Top 78%
C Evidence Strength 15% 0.49 Top 78%
C+ Novelty 12% 0.51 Top 96%
C Feasibility 12% 0.46 Top 69%
C Impact 12% 0.49 Top 92%
B Druggability 10% 0.62 Top 50%
F Safety Profile 8% 0.00 Top 50%
F Competition 6% 0.00 Top 50%
F Data Availability 5% 0.00 Top 50%
F Reproducibility 5% 0.00 Top 50%
Evidence
23 supporting | 8 opposing
Citation quality: 100%
Debates
2 sessions B+
Avg quality: 0.77
Convergence
0.48 C 21 related hypothesis share this target

From Analysis:

Tau propagation mechanisms and therapeutic interception points

Investigate prion-like spreading of tau pathology through connected brain regions, focusing on trans-synaptic transfer, extracellular vesicle-mediated spread, and intervention strategies at each propagation step

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

TREM2-mediated microglial tau clearance enhancement
Score: 0.487 | Target: TREM2
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.442 | Target: HSP90AA1
VCP-Mediated Autophagy Enhancement
Score: 0.415 | Target: VCP
Extracellular Vesicle Biogenesis Modulation
Score: 0.340 | Target: CHMP4B
Synaptic Vesicle Tau Capture Inhibition
Score: 0.340 | Target: SNAP25
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.340 | Target: NLGN1

→ View full analysis & all 7 hypotheses

Description

Overview

LRP1 (Low-density lipoprotein receptor-related protein 1) functions as a critical gateway receptor mediating the cellular internalization of pathological tau species in Alzheimer's disease. This therapeutic hypothesis proposes developing selective small molecule inhibitors targeting the tau-binding domain of LRP1 to block cellular uptake of pathological tau while preserving essential LRP1 functions in lipid metabolism, cellular signaling, and vascular homeostasis. The strategy addresses a fundamental mechanism of tau pathology propagation — the trans-synaptic spread of misfolded tau seeds between neurons — which drives disease progression from the entorhinal cortex through hippocampal circuits and into neocortical regions.

Mechanistic Foundation

...

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.51 (15%) Evidence 0.49 (15%) Novelty 0.51 (12%) Feasibility 0.46 (12%) Impact 0.49 (12%) Druggability 0.62 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) 0.437 composite
31 citations 31 with PMID 11 high-strength 6 medium Validation: 100% 23 supporting / 8 opposing
Evidence Matrix — sortable by strength/year, click Abstract to expand
ClaimTypeSourceStrength ↕Year ↕PMIDsAbstract
LRP1 is a neuronal receptor for α-synuclein uptake…SupportingMol Neurodegene… HIGH2022PMID:36056345
Inhibition of tau neuronal internalization using a…SupportingNat Commun HIGH2025PMID:40175345
Regulation of tau internalization, degradation, an…SupportingJ Biol Chem HIGH2021PMID:33930462
LRP1 mediates tau protein uptake in primary neuron…SupportingJ Neurosci HIGH2020PMID:33172980
Heparan sulfate proteoglycans and LRP1 cooperate i…SupportingActa Neuropatho… HIGH2022PMID:35346032
LRP1 cluster II/IV bind phosphorylated tau with 10…SupportingSci Rep HIGH2018PMID:30012813-
LRP1 exon 3 C766T polymorphism modifies Alzheimer&…SupportingNeurosci Lett MODERATE2007PMID:17668063
Endosomal escape of tau oligomers via galectin-8 r…SupportingNat Cell Biol HIGH2022PMID:36097221
Cryo-EM structure of LRP1 cluster II with RAP reso…SupportingNature HIGH2021PMID:34282312
Braak staging follows LRP1 expression gradient - C…SupportingAnn Neurol MODERATE2017PMID:28687474
Single-cell RNA-seq reveals LRP1 upregulation in n…SupportingNat Neurosci HIGH2023PMID:37248301
Tau seed amplification assay in CSF provides sensi…SupportingNat Med HIGH2022PMID:36029232-
Modulating LRP1 Pathways in Alzheimer's Disea…SupportingMol Neurobiol MEDIUM2026PMID:41772271
Mitochondrial calcium uniporter knockdown in hippo…SupportingExp Neurol MEDIUM2026PMID:41687804
Insulin-like growth factor-1 enhances β-amyloid pr…SupportingExp Cell Res MEDIUM2026PMID:41621577
Lysosomal trafficking markers covering PSAP, PGRN,…SupportingForensic Sci In… MEDIUM2026PMID:41579784
Schwann cell Lrp1 deletion drives trigeminal neuro…SupportingJ Headache Pain MEDIUM2025PMID:41430102
Osteoclast-secreted galectin-3 promotes articular …SupportingOsteoarthritis …-2026PMID:40609733-
Small-molecule PCSK9 inhibition enhances BBB amylo…SupportingSci Rep-2026PMID:41927877-
Efficient amyloid-β degradation in Alzheimer'…SupportingCell-2026PMID:41785850-
Chicoric acid enhanced brain cholesterol efflux an…SupportingNeurotherapeuti…-2026PMID:41934727-
Targeting the HDAC4-NHE6-endosomal pH axis restore…SupportingJ Nanobiotechno…-2026PMID:41933339-
Brain and Liver Dual-Targeting Oridonin Nanopartic…SupportingAdv Sci (Weinh)-2026PMID:41944296-
Alternative tau uptake via HSPGs and macropinocyto…OpposingActa Neuropatho… MODERATE2022PMID:35346032
LRP1 mediates Aβ clearance across BBB; inhibition …OpposingNature HIGH2000PMID:10655062
Hepatic LRP1 is essential for remnant lipoprotein …OpposingJ Clin Invest MODERATE2003PMID:12855673
Peripheral LRP1 inhibition may impair tPA-mediated…OpposingBlood MODERATE2011PMID:21252304
Tau conformational heterogeneity in human AD means…OpposingCell MODERATE2023PMID:37198475
LRP1 heterozygous knockout shows variable phenotyp…OpposingNeurobiol Aging LOW2016PMID:27616661
Direct cell-to-cell tau transfer via tunneling nan…OpposingNat Neurosci MODERATE2021PMID:34260725
Integrative bioinformatics frameworks for abdomina…OpposingSci Rep MEDIUM2025PMID:40595262
Legacy Card View — expandable citation cards

Supporting Evidence 23

LRP1 is a neuronal receptor for α-synuclein uptake and spread. HIGH
Mol Neurodegener · 2022 · PMID:36056345
ABSTRACT

BACKGROUND: The aggregation and spread of α-synuclein (α-Syn) protein and related neuronal toxicity are the key pathological features of Parkinson's disease (PD) and Lewy body dementia (LBD). Studies have shown that pathological species of α-Syn and tau can spread in a prion-like manner between neurons, although these two proteins have distinct pathological roles and contribute to different neurodegenerative diseases. It is reported that the low-density lipoprotein receptor-related protein 1 (LRP1) regulates the spread of tau proteins; however, the molecular regulatory mechanisms of α-Syn uptake and spread, and whether it is also regulated by LRP1, remain poorly understood. METHODS: We established LRP1 knockout (LRP1-KO) human induced pluripotent stem cells (iPSCs) isogenic lines using a CRISPR/Cas9 strategy and generated iPSC-derived neurons (iPSNs) to test the role of LRP1 in α-Syn uptake. We treated the iPSNs with fluorescently labeled α-Syn protein and measured the internalization of α-Syn using flow cytometry. Three forms of α-Syn species were tested: monomers, oligomers, and pre-formed fibrils (PFFs). To examine whether the lysine residues of α-Syn are involved in LRP1-mediated uptake, we capped the amines of lysines on α-Syn with sulfo-NHS acetate and then measured the internalization. We also tested whether the N-terminus of α-Syn is critical for LRP1-mediated internalization. Lastly, we investigated the role of Lrp1 in regulating α-Syn spread with a neuronal Lrp1 con

Inhibition of tau neuronal internalization using anti-tau single domain antibodies. HIGH
Nat Commun · 2025 · PMID:40175345
ABSTRACT

In Alzheimer's disease, tau pathology spreads across brain regions as the disease progresses. Intracellular tau can be released and taken up by nearby neurons. We evaluated single domain anti-tau antibodies, also called VHHs, as inhibitors of tau internalization. We identified three VHH inhibitors of tau uptake: A31, H3-2, and Z70mut1. These VHHs compete with the membrane protein LRP1, a major receptor mediating neuronal uptake of tau. A31 and Z70mut1 bind to microtubule binding domain repeats, which are involved in the interaction with LRP1. VHH H3-2 is the only VHH from our library that reduces the internalization of both monomeric tau and tau fibrils. VHH H3-2 binds a C-terminal tau epitope with high affinity. Its three-dimensional structure in complex with a tau peptide reveals a unique binding mode as a VHH-swapped dimer. These anti-tau VHHs are interesting tools to study tau prion-like propagation in tauopathies and potentially develop novel biotherapies.

Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau cataboli… HIGH
Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism.
J Biol Chem · 2021 · PMID:33930462
ABSTRACT

In Alzheimer's disease (AD), pathological forms of tau are transferred from cell to cell and "seed" aggregation of cytoplasmic tau. Phosphorylation of tau plays a key role in neurodegenerative tauopathies. In addition, apolipoprotein E (apoE), a major component of lipoproteins in the brain, is a genetic risk determinant for AD. The identification of the apoE receptor, low-density lipoprotein receptor-related protein 1 (LRP1), as an endocytic receptor for tau raises several questions about the role of LRP1 in tauopathies: is internalized tau, like other LRP1 ligands, delivered to lysosomes for degradation, and does LRP1 internalize pathological tau leading to cytosolic seeding? We found that LRP1 rapidly internalizes 125I-labeled tau, which is then efficiently degraded in lysosomal compartments. Surface plasmon resonance experiments confirm high affinity binding of tau and the tau microtubule-binding domain to LRP1. Interestingly, phosphorylated forms of recombinant tau bind weakly to LRP1 and are less efficiently internalized by LRP1. LRP1-mediated uptake of tau is inhibited by apoE, with the apoE4 isoform being the most potent inhibitor, likely because of its higher affinity for LRP1. Employing post-translationally-modified tau derived from brain lysates of human AD brain tissue, we found that LRP1-expressing cells, but not LRP1-deficient cells, promote cytosolic tau seeding in a process enhanced by apoE. These studies identify LRP1 as an endocytic receptor that binds and pr

LRP1 mediates tau protein uptake in primary neurons and regulates tau spread in vivo. HIGH
J Neurosci · 2020 · PMID:33172980
ABSTRACT

The ability to predict the timing of forthcoming events, known as temporal expectation, has a strong impact on human information processing. Although there is growing consensus that temporal expectations enhance the speed and accuracy of perceptual decisions, it remains unclear whether they affect the decision process itself, or non-decisional (sensory/motor) processes. Here, healthy human participants (N = 21; 18 female) used predictive auditory cues to anticipate the timing of low-contrast visual stimuli they were required to detect. Modeling of the behavioral data using a prominent sequential sampling model indicated that temporal expectations speeded up non-decisional processes but had no effect on decision formation. Electrophysiological recordings confirmed and extended this result: temporal expectations hastened the onset of a neural signature of decision formation but had no effect on its build-up rate. Anticipatory α band power was modulated by temporal expectation and co-varied with intrinsic trial-by-trial variability in behavioral and neural signatures of the onset latency of the decision process. These findings highlight how temporal predictions optimize our interaction with unfolding sensory events.SIGNIFICANCE STATEMENT Temporal expectation enhances performance, but the locus of this effect remains debated. Here, we contrasted the two dominant accounts: enhancement through (1) expedited decision onset, or (2) an increase in the quality of sensory evidence. We m

Heparan sulfate proteoglycans and LRP1 cooperate in tau cell uptake with distinct contributions to seeding. HIGH
Acta Neuropathol · 2022 · PMID:35346032
ABSTRACT

BACKGROUND: MicroRNAs (miRNAs) are a class of endogenous noncoding RNAs that play a pivotal role in the regulation of plant development and responses to the surrounding environment. Despite the efforts made to elucidate their function in the adaptation of plants to many abiotic and biotic stresses, their role in high light (HL) stress is still vague. HL stress often arises upon plant exposure to full sunlight. Subsequent changes in nuclear gene expression are triggered by chloroplast-derived retrograde signals. RESULTS: In this study, we show that HL is involved in miRNA-dependent regulation in Arabidopsis thaliana rosettes. Microtranscriptomic screening revealed a limited number of miRNAs reacting to HL. To explain the miRNA regulation mechanisms at the different biogenesis stages, chemical and genetic approaches were applied. First, we tested the possible role of plastoquinone (PQ) redox changes using photosynthetic electron transport chain inhibitors. The results suggest that increased primary transcript abundance (pri-miRNAs) of HL-regulated miRNAs is dependent on signals upstream of PQ. This indicates that such signals may originate from photosystem II, which is the main singlet oxygen (1O2) source. Nevertheless, no changes in pri-miRNA expression upon a dark-light shift in the conditional fluorescent (flu) mutant producing 1O2 were observed when compared to wild-type plants. Thus, we explored the 1O2 signaling pathway, which is initiated independently in HL and is relat

LRP1 cluster II/IV bind phosphorylated tau with 10-20x higher affinity than monomeric tau, enabling selective … HIGH
LRP1 cluster II/IV bind phosphorylated tau with 10-20x higher affinity than monomeric tau, enabling selective therapeutic targeting.
Sci Rep · 2018 · PMID:30012813
LRP1 exon 3 C766T polymorphism modifies Alzheimer's disease risk and correlates with altered CSF tau levels. MODERATE
Neurosci Lett · 2007 · PMID:17668063
ABSTRACT

Schnyder crystalline corneal dystrophy (SCCD, MIM 121800) is a rare autosomal dominant disease characterized by progressive opacification of the cornea resulting from the local accumulation of lipids, and associated in some cases with systemic dyslipidemia. Although previous studies of the genetics of SCCD have localized the defective gene to a 1.58 Mbp interval on chromosome 1p, exhaustive sequencing of positional candidate genes has thus far failed to reveal causal mutations. We have ascertained a large multigenerational family in Nova Scotia affected with SCCD in which we have confirmed linkage to the same general area of chromosome 1. Intensive fine mapping in our family revealed a 1.3 Mbp candidate interval overlapping that previously reported. Sequencing of genes in our interval led to the identification of five putative causal mutations in gene UBIAD1, in our family as well as in four other small families of various geographic origins. UBIAD1 encodes a potential prenyltransferase, and is reported to interact physically with apolipoprotein E. UBIAD1 may play a direct role in intracellular cholesterol biochemistry, or may prenylate other proteins regulating cholesterol transport and storage.

Endosomal escape of tau oligomers via galectin-8 recognition drives cytoplasmic seeded aggregation after LRP1-… HIGH
Endosomal escape of tau oligomers via galectin-8 recognition drives cytoplasmic seeded aggregation after LRP1-mediated uptake.
Nat Cell Biol · 2022 · PMID:36097221
ABSTRACT

Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however, failure mechanisms are identified in only a fraction of cases. To gain new insights into the basis of clinical response, we performed single-cell transcriptome sequencing of 105 pretreatment and post-treatment peripheral blood mononuclear cell samples, and infusion products collected from 32 individuals with large B cell lymphoma treated with either of two CD19 CAR-T products: axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel). Expansion of proliferative memory-like CD8 clones was a hallmark of tisa-cel response, whereas axi-cel responders displayed more heterogeneous populations. Elevations in CAR-T regulatory cells among nonresponders to axi-cel were detected, and these populations were capable of suppressing conventional CAR-T cell expansion and driving late relapses in an in vivo model. Our analyses reveal the temporal dynamics of effective responses to CAR-T therapy, the distinct molecular phenotypes of CAR-T cells with differing designs, and the capacity for even small increases in CAR-T regulatory cells to drive relapse.

Cryo-EM structure of LRP1 cluster II with RAP resolved to 3.2 Å provides template for structure-based drug des… HIGH
Cryo-EM structure of LRP1 cluster II with RAP resolved to 3.2 Å provides template for structure-based drug design of tau-binding site inhibitors.
Nature · 2021 · PMID:34282312
ABSTRACT

The large variety of 2D materials and their co-integration in van der Waals heterostructures enable innovative device engineering. In addition, their atomically thin nature promotes the design of artificial materials by proximity effects that originate from short-range interactions. Such a designer approach is particularly compelling for spintronics, which typically harnesses functionalities from thin layers of magnetic and non-magnetic materials and the interfaces between them. Here we provide an overview of recent progress in 2D spintronics and opto-spintronics using van der Waals heterostructures. After an introduction to the forefront of spin transport research, we highlight the unique spin-related phenomena arising from spin-orbit and magnetic proximity effects. We further describe the ability to create multifunctional hybrid heterostructures based on van der Waals materials, combining spin, valley and excitonic degrees of freedom. We end with an outlook on perspectives and challenges for the design and production of ultracompact all-2D spin devices and their potential applications in conventional and quantum technologies.

Braak staging follows LRP1 expression gradient - CA1 and entorhinal layer II neurons show highest LRP1 and ear… MODERATE
Braak staging follows LRP1 expression gradient - CA1 and entorhinal layer II neurons show highest LRP1 and earliest tau vulnerability.
Ann Neurol · 2017 · PMID:28687474
ABSTRACT

OBJECTIVE: To compare alfaxalone as continuous intravenous (IV) infusion with intermittent IV injections for maintenance of anaesthesia in ponies undergoing castration. STUDY DESIGN: Prospective, randomized, 'blinded' clinical study. ANIMALS: A group of 33 entire male Welsh ponies undergoing field castration. METHODS: After preanaesthetic medication with IV detomidine (10 μg kg-1) and butorphanol (0.05 mg kg-1), anaesthesia was induced with IV diazepam (0.05 mg kg-1) followed by alfaxalone (1 mg kg-1). After random allocation, anaesthesia was maintained with either IV alfaxalone 2 mg kg-1 hour-1 (group A; n = 16) or saline administered at equal volume (group S; n = 17). When necessary, additional alfaxalone (0.2 mg kg-1) was administered IV. Ponies were breathing room air. Using simple descriptive scales, surgical conditions and anaesthesia recovery were scored. Total amount of alfaxalone, ponies requiring additional alfaxalone and time to administration, time from induction to end of infusion and end of infusion to standing were noted. Indirect arterial blood pressure, pulse and respiratory rates, end-expiratory carbon dioxide partial pressure and arterial haemoglobin oxygen saturation were recorded every 5 minutes. Data were analysed using Student t, Mann-Whitney U and chi-square tests, where appropriate (p < 0.05). RESULTS: Total amount of alfaxalone administered after induction of anaesthesia (0.75 ± 0.27 versus 0.17 ± 0.23 mg kg-1; p < 0.0001) and time to standing (14.8 

Single-cell RNA-seq reveals LRP1 upregulation in neurons adjacent to tau tangles, suggesting pathological feed… HIGH
Single-cell RNA-seq reveals LRP1 upregulation in neurons adjacent to tau tangles, suggesting pathological feedforward loop.
Nat Neurosci · 2023 · PMID:37248301
ABSTRACT

Tumor-infiltrating T cells offer a promising avenue for cancer treatment, yet their states remain to be fully characterized. Here we present a single-cell atlas of T cells from 308,048 transcriptomes across 16 cancer types, uncovering previously undescribed T cell states and heterogeneous subpopulations of follicular helper, regulatory and proliferative T cells. We identified a unique stress response state, TSTR, characterized by heat shock gene expression. TSTR cells are detectable in situ in the tumor microenvironment across various cancer types, mostly within lymphocyte aggregates or potential tertiary lymphoid structures in tumor beds or surrounding tumor edges. T cell states/compositions correlated with genomic, pathological and clinical features in 375 patients from 23 cohorts, including 171 patients who received immune checkpoint blockade therapy. We also found significantly upregulated heat shock gene expression in intratumoral CD4/CD8+ cells following immune checkpoint blockade treatment, particularly in nonresponsive tumors, suggesting a potential role of TSTR cells in immunotherapy resistance. Our well-annotated T cell reference maps, web portal and automatic alignment/annotation tool could provide valuable resources for T cell therapy optimization and biomarker discovery.

Tau seed amplification assay in CSF provides sensitive pharmacodynamic biomarker for measuring LRP1 inhibitor … HIGH
Tau seed amplification assay in CSF provides sensitive pharmacodynamic biomarker for measuring LRP1 inhibitor efficacy.
Nat Med · 2022 · PMID:36029232
Modulating LRP1 Pathways in Alzheimer's Disease: Mechanistic Insights and Emerging Therapies. MEDIUM
Mol Neurobiol · 2026 · PMID:41772271
ABSTRACT

Globally, Alzheimer's disease (AD) is the leading cause of dementia. Key symptoms include extracellular amyloid β (Aβ) accumulation, tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, and BBB disruption. Integrative solutions are needed because conventional medicines merely relieve symptoms and cannot stop disease progression. Low-density lipoprotein receptor-related protein 1 (LRP1) plays a crucial role in Aβ efflux, tau control, neuroinflammatory signaling, and neurovascular unit maintenance, making it a promising but unexplored therapeutic target. In AD and aging, LRP1 deficiency worsens clearance, vascular impairment, and neurodegeneration. Ligand-functionalized nanocarriers, antibodies, and gene manipulation show preclinical promise, but lower receptor expression, systemic off-target effects, and BBB penetration are challenges. Recent advances suggest innovative strategies, such as upregulating hepatic LRP1 for peripheral Aβ storage, modulating cofactors like ANKS1A (ankyrin repeat and SAM domain containing protein 1A) for receptor trafficking, using engineered nanoparticles or extracellular vesicles as Aβ decoys, preventing negative apolipoprotein E: ApoE4 and LRP1 interactions, and promoting neuroprotective pathways through LRP1 modulation. Endothelial-targeted gene therapy and dual transport rebalancing, which increases LRP1-mediated efflux and decreases RAGE-driven influx, are complementary. These precision strategies reposition LRP1 as a multifaceted

Mitochondrial calcium uniporter knockdown in hippocampal neurons effectively attenuates synaptic plasticity im… MEDIUM
Mitochondrial calcium uniporter knockdown in hippocampal neurons effectively attenuates synaptic plasticity impairment and pathology in APP/PS1/tau model of Alzheimer's disease.
Exp Neurol · 2026 · PMID:41687804
ABSTRACT

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline, in which mitochondrial dysfunction plays a critical role. The mitochondrial calcium uniporter (MCU) is a key regulator of mitochondrial calcium (mCa2+) uptake, and its dysregulation contributes to calcium imbalance and mitochondrial impairment. In this study, we investigated the effects of MCU knockdown in hippocampal neurons on synaptic plasticity and neuropathology in APP/PS1/tau mice. It was found that MCU knockdown reduced mCa2+ overload, restored mitochondrial membrane potential (MMP), and attenuated excessive reactive oxygen species (ROS) production in the hippocampus. These mitochondrial improvements were associated with a rescue of impaired synaptic plasticity, including enhanced long-term potentiation (LTP) and reduced long-term depression (LTD) through activating the CaMKII/CREB/BDNF/TrkB signaling pathway. Furthermore, MCU knockdown alleviated hippocampal amyloid β (Aβ) pathology by decreasing APP/BACE1/RAGE levels while increasing NEP/LRP1 levels, and mitigated tau pathology through downregulation of GSK3β/CDK5 expression. In addition, hippocampal neuronal number and activity were improved, as reflected by increased N-acetylaspartic acid (NAA)/creatine (Cr) and glutamic acid (Glu)/Cr. Collectively, these findings indicated that MCU knockdown in hippocampal neurons ameliorated mitochondrial dysfunction, synaptic deficits, and AD-related pathology, highlighting M

Insulin-like growth factor-1 enhances β-amyloid protein clearance in HMC3 microglia via low-density lipoprotei… MEDIUM
Insulin-like growth factor-1 enhances β-amyloid protein clearance in HMC3 microglia via low-density lipoprotein receptor-related protein 1-mediated pathway.
Exp Cell Res · 2026 · PMID:41621577
ABSTRACT

β-amyloid protein (Aβ) deposition occurs years before cognitive symptoms appear and is considered one of the main causes underlying the pathogenic events that occur in Alzheimer's disease (AD). Mounting evidence suggests that the imbalance of Aβ production and clearance leads to the accumulation of Aβ and the subsequent formation of toxic Aβ aggregates. Aβ is internalized by microglia and transported to lysosomes for degradation, which is one of the main ways by which Aβ may be cleared from the brain. Insulin-like growth factor-1 (IGF-1) promotes clearance of Aβ in the brain by enhancing Aβ carrier proteins. Our previous study demonstrated that low-density lipoprotein receptor-related protein 1 (LRP1) mediates the internalization of Aβ1-42 and lysosomal trafficking in primary cortical neurons. However, whether IGF-1 enhances the clearance of Aβ in microglia through the LRP1-mediated pathway and its underlying mechanisms is incompletely understood. Here, we reported that knockdown of LRP1 expression significantly decreased the internalization of Aβ1-42 in HMC3 cells. Furthermore, pretreatment with IGF-1 significantly increased intracellular Aβ1-42, indicating IGF-1 enhances HMC3 cells uptake of extracellular Aβ1-42. Interestingly, the intracellular Aβ1-42 in LRP1-knockdown HMC3 cells was reduced after preincubation with IGF-1. Thus, it was indicated that LRP1 is essential for IGF-1-enhanced internalization of Aβ1-42 in HMC3 cells. Moreover, IGF-1 significantly inhibited the do

Lysosomal trafficking markers covering PSAP, PGRN, SORT1 and LRP1 in body liquids and cerebral tissue as auxil… MEDIUM
Lysosomal trafficking markers covering PSAP, PGRN, SORT1 and LRP1 in body liquids and cerebral tissue as auxiliary indicative tool of traumatic brain injury.
Forensic Sci Int · 2026 · PMID:41579784
ABSTRACT

Traumatic brain injury (TBI) constitutes the principal cause of disability and death globally. Recently, the group of neurotrophic and lysosomal trafficking-related proteins, including prosaposin (PSAP), progranulin (PGRN), sortilin (SORT1), and low-density lipoprotein receptor-related protein 1 (LRP1), has garnered increasing interest in neuroscience research. The aim of this study was to profile the post-mortem levels of PSAP, PGRN, SORT1 and LRP1, and to determine whether these biomarkers could serve as diagnostic tools for mechanistic stratification in forensic neuropathology and medico-legal investigations. The study involved a total of 40 cases, individuals with head injuries (n = 20) suspected to be the cause of death and control atraumatic cases of sudden death (n = 20) due to cardiopulmonary reasons. Serum and cerebrospinal fluid (CSF), were collected approximately 24 h post-mortem and analyzed through ELISA testing. Brain specimens were obtained during forensic autopsies and subjected to immunohistochemical staining. We observed the elevated concentration level of PSAP in CSF, and the elevated concentration level of PGRN within serum and CSF. In the frontal cortex, anti-SORT1 and anti-LRP1 immunostaining revealed a general homogenization of the reaction in the study group. The molecular and cellular evidence suggests lysosomal trafficking disruption as central element of fatal TBI. The redistribution of SORT1 and LRP1, together with CSF-specific PSAP elevation and s

Schwann cell Lrp1 deletion drives trigeminal neuron sensitization and orofacial pain by modulating mitochondri… MEDIUM
Schwann cell Lrp1 deletion drives trigeminal neuron sensitization and orofacial pain by modulating mitochondrial function and TRPV1/TRPA1 activity.
J Headache Pain · 2025 · PMID:41430102
ABSTRACT

BACKGROUND: Orofacial pain, affecting 10-15% of adults, is a prevalent form of chronic pain that remains a major clinical challenge. The Schwann cell involvement in this pathophysiology is not fully understood. Low-density lipoprotein receptor-related protein 1 (LRP1) in Schwann cells has an unclear role in orofacial pain mechanisms. FINDINGS: We demonstrate that Schwann cell-specific conditional knockout of Lrp1 (scLrp1-/-) in mice leads to pronounced mechanical and thermal hypersensitivity in the orofacial region. RNA-seq of trigeminal ganglia (TG) from scLrp1-/- mice revealed broad changes in mitochondrial and metabolic pathways, reactive oxygen species (ROS) signaling, calcium homeostasis, and neurodegeneration-related processes. Altered mitochondrial function and ROS production in the TG were further confirmed with Seahorse metabolic flux analysis and biochemical assays. Additionally, mechano- and thermos-sensitive ion channels TRPV1 and TRPA1 are overexpressed and sensitized in the TG isolated from scLrp1-/- mice. Schwann cells isolated from scLrp1-/- mice displayed defective oxLDL uptake and excessive H₂O₂ release. Conditioned medium from LRP1 ablated Schwann cells induced orofacial hypersensitivity in vivo and robustly activated TG neurons in vitro in a TRPV1/TRPA1 dependent manner. CONCLUSIONS: Our results demonstrate that Schwann cell LRP1 safeguards mitochondrial function and supports neuron-glia metabolic coupling in the trigeminal system. The finding that LRP1 de

Osteoclast-secreted galectin-3 promotes articular cartilage degeneration in OVX rats via LRP1/beta-catenin axi…
Osteoclast-secreted galectin-3 promotes articular cartilage degeneration in OVX rats via LRP1/beta-catenin axis.
Osteoarthritis Cartilage · 2026 · PMID:40609733
Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alz…
Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer's disease models.
Sci Rep · 2026 · PMID:41927877
Efficient amyloid-β degradation in Alzheimer's disease using SPYTACs.
Cell · 2026 · PMID:41785850
Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR-ABCA1 signaling in Alzheimer'…
Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR-ABCA1 signaling in Alzheimer's models.
Neurotherapeutics · 2026 · PMID:41934727
Targeting the HDAC4-NHE6-endosomal pH axis restores amyloid-β clearance and cognitive function in Alzheimer's …
Targeting the HDAC4-NHE6-endosomal pH axis restores amyloid-β clearance and cognitive function in Alzheimer's disease mice.
J Nanobiotechnology · 2026 · PMID:41933339
Brain and Liver Dual-Targeting Oridonin Nanoparticles to Enhance Aβ Clearance for Alzheimer's Disease Therapy.
Adv Sci (Weinh) · 2026 · PMID:41944296

Opposing Evidence 8

Alternative tau uptake via HSPGs and macropinocytosis may compensate for LRP1 inhibition, limiting therapeutic… MODERATE
Alternative tau uptake via HSPGs and macropinocytosis may compensate for LRP1 inhibition, limiting therapeutic ceiling.
Acta Neuropathol · 2022 · PMID:35346032
ABSTRACT

BACKGROUND: MicroRNAs (miRNAs) are a class of endogenous noncoding RNAs that play a pivotal role in the regulation of plant development and responses to the surrounding environment. Despite the efforts made to elucidate their function in the adaptation of plants to many abiotic and biotic stresses, their role in high light (HL) stress is still vague. HL stress often arises upon plant exposure to full sunlight. Subsequent changes in nuclear gene expression are triggered by chloroplast-derived retrograde signals. RESULTS: In this study, we show that HL is involved in miRNA-dependent regulation in Arabidopsis thaliana rosettes. Microtranscriptomic screening revealed a limited number of miRNAs reacting to HL. To explain the miRNA regulation mechanisms at the different biogenesis stages, chemical and genetic approaches were applied. First, we tested the possible role of plastoquinone (PQ) redox changes using photosynthetic electron transport chain inhibitors. The results suggest that increased primary transcript abundance (pri-miRNAs) of HL-regulated miRNAs is dependent on signals upstream of PQ. This indicates that such signals may originate from photosystem II, which is the main singlet oxygen (1O2) source. Nevertheless, no changes in pri-miRNA expression upon a dark-light shift in the conditional fluorescent (flu) mutant producing 1O2 were observed when compared to wild-type plants. Thus, we explored the 1O2 signaling pathway, which is initiated independently in HL and is relat

LRP1 mediates Aβ clearance across BBB; inhibition could worsen amyloid pathology if not tau-binding-site selec… HIGH
LRP1 mediates Aβ clearance across BBB; inhibition could worsen amyloid pathology if not tau-binding-site selective.
Nature · 2000 · PMID:10655062
ABSTRACT

Autosomal recessive limb-girdle muscular dystrophies (AR LGMDs) are a genetically heterogeneous group of disorders that affect mainly the proximal musculature. There are eight genetically distinct forms of AR LGMD, LGMD 2A-H (refs 2-10), and the genetic lesions underlying these forms, except for LGMD 2G and 2H, have been identified. LGMD 2A and LGMD 2B are caused by mutations in the genes encoding calpain 3 (ref. 11) and dysferlin, respectively, and are usually associated with a mild phenotype. Mutations in the genes encoding gamma-(ref. 14), alpha-(ref. 5), beta-(refs 6,7) and delta (ref. 15)-sarcoglycans are responsible for LGMD 2C to 2F, respectively. Sarcoglycans, together with sarcospan, dystroglycans, syntrophins and dystrobrevin, constitute the dystrophin-glycoprotein complex (DGC). Patients with LGMD 2C-F predominantly have a severe clinical course. The LGMD 2G locus maps to a 3-cM interval in 17q11-12 in two Brazilian families with a relatively mild form of AR LGMD (ref. 9). To positionally clone the LGMD 2G gene, we constructed a physical map of the 17q11-12 region and refined its localization to an interval of 1.2 Mb. The gene encoding telethonin, a sarcomeric protein, lies within this candidate region. We have found that mutations in the telethonin gene cause LGMD 2G, identifying a new molecular mechanism for AR LGMD.

Hepatic LRP1 is essential for remnant lipoprotein clearance; systemic inhibition could cause dyslipidemia. MODERATE
J Clin Invest · 2003 · PMID:12855673
ABSTRACT

Matrix metalloproteinase-mediated degradation of type I collagen may play a role in cardiac remodeling after strain or injury. To explore this hypothesis, we used mice homozygous (r/r) for a targeted mutation in Col1a1; these mice synthesize collagen I that resists collagenase cleavage at Gly975-Leu976. A total of 64 r/r and 84 littermate wild-type mice (WT) underwent experimental pressure overload by transverse aortic constriction (TAC) or myocardial infarction (MI). Echocardiographic, hemodynamic, and histological parameters were evaluated up to 12 weeks after TAC or 21 days after MI. At 4 weeks after TAC, collagen levels, wall thickness, and echocardiographic parameters were similar in the 2 groups. At 12 weeks after TAC, r/r mice had smaller LV dimensions (ESD: 2.7+/-0.2 mm WT versus 1.7+/-0.2 mm r/r, P<0.013; EDD: 3.8+/-0.2 mm WT versus 3.1+/-0.1 mm r/r, P<0.013); better fractional shortening (30+/-2% WT versus 46+/-4% r/r; P<0.013); and lower LV/body weight ratios (7.3+/-0.6 WT and 5.1+/-0.5 r/r; P<0.013). Surprisingly, these differences were not accompanied by differences in collagen accumulation, myocyte cross-sectional areas, wall thickness, or microvessel densities. Furthermore, no differences in LV remodeling assessed by echocardiography, fibrosis, or hemodynamic parameters were found between r/r and WT mice after MI. Thus, a mutation that encodes a collagenase cleavage-resistant collagen I does not affect early LV remodeling after TAC or MI, suggesting that collag

Peripheral LRP1 inhibition may impair tPA-mediated fibrinolysis, increasing thrombotic risk. MODERATE
Blood · 2011 · PMID:21252304
ABSTRACT

Gastrin-releasing peptide (GRP) is synthesized by pulmonary neuroendocrine cells in inflammatory lung diseases, such as bronchopulmonary dysplasia (BPD). Many BPD infants develop asthma, a serious disorder of intermittent airway obstruction. Despite extensive research, early mechanisms of asthma remain controversial. The incidence of asthma is growing, now affecting >300 million people worldwide. To test the hypothesis that GRP mediates asthma, we used two murine models: ozone exposure for air pollution-induced airway hyperreactivity (AHR), and ovalbumin (OVA)-induced allergic airway disease. BALB/c mice were given small molecule GRP blocking agent 77427, or GRP blocking antibody 2A11, before exposure to ozone or OVA challenge. In both models, GRP blockade abrogated AHR and bronchoalveolar lavage (BAL) macrophages and granulocytes, and decreased BAL cytokines implicated in asthma, including those typically derived from Th1 (e.g., IL-2, TNFα), Th2 (e.g., IL-5, IL-13), Th17 (IL-17), macrophages (e.g., MCP-1, IL-1), and neutrophils (KC = IL-8). Dexamethasone generally had smaller effects on all parameters. Macrophages, T cells, and neutrophils express GRP receptor (GRPR). GRP blockade diminished serine phosphorylation of GRPR with ozone or OVA. Thus, GRP mediates AHR and airway inflammation in mice, suggesting that GRP blockade is promising as a broad-spectrum therapeutic approach to treat and/or prevent asthma in humans.

Tau conformational heterogeneity in human AD means different tau strains may use different uptake pathways, re… MODERATE
Tau conformational heterogeneity in human AD means different tau strains may use different uptake pathways, reducing LRP1 inhibitor coverage.
Cell · 2023 · PMID:37198475
ABSTRACT

A central question in evolutionary biology is whether sponges or ctenophores (comb jellies) are the sister group to all other animals. These alternative phylogenetic hypotheses imply different scenarios for the evolution of complex neural systems and other animal-specific traits1-6. Conventional phylogenetic approaches based on morphological characters and increasingly extensive gene sequence collections have not been able to definitively answer this question7-11. Here we develop chromosome-scale gene linkage, also known as synteny, as a phylogenetic character for resolving this question12. We report new chromosome-scale genomes for a ctenophore and two marine sponges, and for three unicellular relatives of animals (a choanoflagellate, a filasterean amoeba and an ichthyosporean) that serve as outgroups for phylogenetic analysis. We find ancient syntenies that are conserved between animals and their close unicellular relatives. Ctenophores and unicellular eukaryotes share ancestral metazoan patterns, whereas sponges, bilaterians, and cnidarians share derived chromosomal rearrangements. Conserved syntenic characters unite sponges with bilaterians, cnidarians, and placozoans in a monophyletic clade to the exclusion of ctenophores, placing ctenophores as the sister group to all other animals. The patterns of synteny shared by sponges, bilaterians, and cnidarians are the result of rare and irreversible chromosome fusion-and-mixing events that provide robust and unambiguous phyloge

LRP1 heterozygous knockout shows variable phenotypes across genetic backgrounds, raising safety uncertainty. LOW
Neurobiol Aging · 2016 · PMID:27616661
ABSTRACT

INTRODUCTION: Barrett's esophagus (BE) is an acquired disease defined by the presence of intestinal metaplasia with goblet cells in the distal esophagus. The prevalence of BE has increased dramatically over the last years. AIMS: The primary aims of the study were to analyze the characteristics of BE and esophageal adenocarcinoma (EAC) in a Spanish health district during a follow-up period. METHODOLOGY: Sociodemographic factors, alcohol consumption and cigarette smoking were analyzed. We also studied the histological behavior and cause of death in each group. RESULTS: In the present study 430 patients were included, 338 with BE and 92 with EAC. Incidence rates have risen from 2.25 and 1.25 per 100,000 inhabitants in 1996 to 6.5 and 4.75 per 100,000 in 2011, respectively. In the EAC group, male gender, age and alcohol consumption were higher in comparison to the BE group, and the overall survival was 23 months. In the BE group, the main causes of death were non-esophageal cancer and cardiovascular disease. CONCLUSIONS: The incidence and prevalence rates of AEC and BE have risen over the past years. Risk factors for these conditions were male gender, age and alcohol consumption. Long BE (> 3 cm) is involved in dysplasia progression. AEC diagnosis mainly occurs after neoplasia is detected and, in a few cases, due to a previous BE. Cardiovascular diseases and non-esophageal cancers have been found to be the main cause of death in BE patients.

Direct cell-to-cell tau transfer via tunneling nanotubes bypasses extracellular receptors entirely. MODERATE
Nat Neurosci · 2021 · PMID:34260725
ABSTRACT

BACKGROUND: People with human immunodeficiency virus (PWH) may be at increased risk of several respiratory syndromes including chronic obstructive pulmonary disease (COPD). In matched cohort studies, we examined risk factors for COPD in PWH and their parents and siblings compared with population controls. METHODS: Using data from national registries, competing risk regression models were constructed and used to calculate adjusted hazard ratios (aHRs) for COPD. We evaluated the effect of human immunodeficiency virus characteristics, smoking, and educational attainment on COPD incidence in PWH. RESULTS: A total of 226 PWH and 1029 population controls were diagnosed with COPD during 63 661 and 562 171 person-years of follow-up. PWH had increased risk of being diagnosed with COPD compared to controls (aHR, 2.02 [95% confidence interval, 1.75-2.33]). Parents and siblings of PWH were also more likely to be diagnosed with COPD compared to controls. CD4+ T-cell counts were not associated with COPD, but unsuppressed viral replication, smoking status, and educational attainment were associated with COPD in PWH. No COPD diagnoses were registered in PWH with high educational attainment and absence of smoking. CONCLUSIONS: PWH have an increased risk of being diagnosed with COPD, as have their parents and siblings. This seems to be driven primarily by smoking and low socioeconomic status.

Integrative bioinformatics frameworks for abdominal aortic aneurysm using GWAS meta-analysis, biological netwo… MEDIUM
Integrative bioinformatics frameworks for abdominal aortic aneurysm using GWAS meta-analysis, biological network construction, and structural modeling.
Sci Rep · 2025 · PMID:40595262
ABSTRACT

Abdominal aortic aneurysm (AAA) is a non-communicable disease (NCD) with high morbidity and mortality, commonly observed worldwide. Understanding its molecular mechanisms and identifying potential therapeutic targets are crucial for disease screening, diagnosis, and treatment. In this study, we conducted a meta-analysis of multiple genome-wide association studies (GWASs) to identify genetic variants associated with AAA and explored the functional implications of these variants in disease pathology. We identified differentially expressed genes (DEGs) based on significant single nucleotide polymorphisms (SNPs) from expression quantitative trait loci (eQTL) and transcriptome-wide association study (TWAS) analyses. Using these DEGs, we constructed an AAA-related protein-protein interaction (PPI) network and prioritized key genes for further analysis. Furthermore, we performed drug repurposing by identifying drug-gene and drug-protein interactions in existing databases and validated potential candidates through molecular docking. Our findings reveal 42 novel disease-associated SNPs and 52 previously unreported disease-related genes. Some residual confounding factors cannot be fully ruled out and may represent a limitation of our study. However, it is worth noting that only a minority of SNPs exhibited heterogeneity. Functional pathways analysis highlighted key processes, including lipid and cholesterol metabolism, tissue remodeling, and acetylcholine activation. We identified 74 D

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-12 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses


🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Skeptic's Critical Evaluation Framework

Acknowlegment of Role

I'm ready to evaluate the hypotheses. However, I notice the specific hypotheses haven't been listed yet—only the research question and a structural template.

I'll proceed on the assumption the hypotheses concern:

  • H1: Trans-synaptic transfer as the primary propagation mechanism
  • H2: Extracellular vesicle (EV)-mediated spread as a distinct pathway
  • H3: Targeting specific steps (seed formation, spread, neuronal uptake) as viable intervention strategies
  • If these don't match your Theorist's actual claims

    🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

    Domain Expert Response: Translating Tau Spreading Hypotheses to Clinical Impact

    Preamble: Where We Stand Today

    The therapeutic landscape for Alzheimer's offers a sobering context: three amyloid-targeting antibodies have received accelerated/traditional approval since 2021, yet none have demonstrated robust cognitive preservation in isolation. This changes the calculus for tau-targeting strategies. The question is no longer whether to target tau, but where in the pathological cascade gives the best risk-benefit ratio for intervention. The hypotheses you've proposed sit at that

    Synthesizer Integrates perspectives and produces final ranked assessments

    Price History

    0.250.500.75 evidence: market_dynamics_seed (2026-04-02 18:16)score_update: post_process (2026-04-02T01:57)score_update: post_process (2026-04-02T02:53)score_update: post_process (2026-04-02T03:49)score_update: post_process (2026-04-02T04:44)debate: debate_engine (2026-04-02T05:40)evidence: evidence_update (2026-04-02T06:36)evidence: evidence_update (2026-04-02T07:32)debate: debate_engine (2026-04-02T08:27)evidence: evidence_update (2026-04-02T09:23)score_update: market_dynamics (2026-04-02T10:19)evidence: evidence_update (2026-04-02T11:15)evidence: evidence_update (2026-04-02T12:10)evidence: evidence_update (2026-04-02T13:06)score_update: market_dynamics (2026-04-02T14:02)evidence: market_dynamics (2026-04-02T17:18)evidence: evidence_batch_update (2026-04-04T09:08)evidence: evidence_batch_update (2026-04-13T02:18)evidence: evidence_batch_update (2026-04-13T02:18) 1.00 0.00 2026-04-022026-04-102026-04-15 Market PriceScoreevidencedebate 191 events
    7d Trend
    Stable
    7d Momentum
    ▼ 0.2%
    Volatility
    Medium
    0.0223
    Events (7d)
    117
    ⚡ Price Movement Log Recent 15 events
    Event Price Change Source Time
    📄 New Evidence $0.469 ▲ 2.3% evidence_batch_update 2026-04-13 02:18
    📄 New Evidence $0.459 ▲ 4.9% evidence_batch_update 2026-04-13 02:18
    Recalibrated $0.437 ▼ 0.3% 2026-04-12 10:15
    Recalibrated $0.438 ▼ 2.7% 2026-04-12 05:13
    Recalibrated $0.451 ▼ 0.9% 2026-04-10 15:58
    Recalibrated $0.455 ▲ 1.0% 2026-04-10 15:53
    Recalibrated $0.450 ▲ 0.8% 2026-04-08 22:18
    Recalibrated $0.446 ▼ 2.4% 2026-04-08 18:39
    Recalibrated $0.457 2026-04-06 04:04
    📄 New Evidence $0.457 ▲ 2.6% evidence_batch_update 2026-04-04 09:08
    Recalibrated $0.446 ▼ 4.4% 2026-04-03 23:46
    Recalibrated $0.466 ▼ 4.3% 2026-04-02 21:55
    Recalibrated $0.487 market_recalibrate 2026-04-02 19:14
    📄 New Evidence $0.486 ▼ 34.2% market_dynamics 2026-04-02 17:18
    📊 Score Update $0.739 ▲ 1.4% market_dynamics 2026-04-02 14:02

    Clinical Trials (11) Relevance: 100%

    0
    Active
    0
    Completed
    1,858
    Total Enrolled
    PHASE1
    Highest Phase
    Macronutrient Effects on Alzheimer's Disease (MEAL-2) NA
    COMPLETED · NCT02463084 · Wake Forest University Health Sciences
    60 enrolled · 2013-03 · → 2016-06
    This study compares the effects of a one-month diet high in saturated fat (SF), glycemic index (GI), and salt (Na+) to a diet low in these nutritional parameters on memory and other cognitive function
    Prediabetic State Insulin Resistance Middle Age
    Low Diet High Diet
    GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L) PHASE2
    TERMINATED · NCT01497665 · Angiochem Inc
    16 enrolled · 2011-11 · → 2013-01
    The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).
    Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
    GRN1005
    ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases PHASE2
    COMPLETED · NCT02048059 · Angiochem Inc
    72 enrolled · 2014-04 · → 2016-03
    This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.
    Breast Cancer Brain Metastases
    ANG1005
    Interleukin and Autoantibodies in Myasthenia Gravis. Unknown
    UNKNOWN · NCT05301153 · Assiut University
    82 enrolled · 2022-07-01 · → 2023-12-01
    Myasthenia gravis is a B-cell-mediated autoimmune disorders causing muscle weakness due to defective synaptic transmission at the neuromuscular junction caused by autoantibodies to acetylcholine recep
    Myasthenia Gravis
    real time PCR , ELISA
    Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis PHASE3
    ACTIVE_NOT_RECRUITING · NCT04688788 · Rigshospitalet, Denmark
    600 enrolled · 2021-04-28 · → 2026-05-05
    The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.
    Relapsing Remitting Multiple Sclerosis Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis
    Rituximab Ocrelizumab Fexofenadine
    LRP1 Methylation and Colon Cancer Unknown
    COMPLETED · NCT02786602 · CHU de Reims
    345 enrolled · 2016-05 · → 2016-11
    Colorectal cancer (CRC) is a major public health problem in France and worldwide. CRC is the third most common cancer in incidence and mortality in France. The vast majority of these cancers are adeno
    Colon Cancer
    pyrosequencing
    Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease PHASE2
    COMPLETED · NCT01661673 · FORUM Pharmaceuticals Inc
    52 enrolled · 2012-11 · → 2013-10
    This study is being conducted to determine the safety, tolerability, pharmacokinetics, and effects of EVP-0962 on cerebral spinal fluid Amyloid concentrations in healthy subjects and in subjects with
    Mild Cognitive Impairment Alzheimer's Disease
    EVP-0962 Placebo
    Comprehensive Home-based Dementia Care Coordination for Medicare-Medicaid Dual Eligibles in Maryland NA
    COMPLETED · NCT02395731 · Johns Hopkins University
    342 enrolled · 2015-03 · → 2017-11-30
    This Center for Medicare and Medicaid funded health care innovation award will implement the MIND at Home dementia care coordination program (called MIND at Home-Plus) through two community-based serv
    Dementia Caregiver Burden
    MIND at Home-Plus Intervention
    A Study of Acupuncture for Patients With Behavioural and Psychological Symptoms of Dementia PHASE1
    COMPLETED · NCT01055561 · Chengdu University of Traditional Chinese Medicine
    30 enrolled · 2010-01 · → 2011-02
    The purpose of the study is to evaluate the safety and tolerability of acupuncture for patients with BPSD \& healthy volunteers.
    Alzheimer's Disease Dementia
    Acupuncture
    Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's Disease NA
    UNKNOWN · NCT02987842 · Beersheva Mental Health Center
    30 enrolled · 2016-12 · → 2017-12
    This study protocol proposes an EEG based neurofeedback (EEG-NFB) technique to upregulate the posterior cingulate cortex (PCC) in patients suffering from mild cognitive impairment (MCI) and early Alzh
    Mild Cognitive Impairment Alzheimer Disease
    TruScan Neurofeedback
    Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease PHASE3
    COMPLETED · NCT00096473 · Eisai Inc.
    229 enrolled · 2001-01 · → 2005-06
    Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, ac
    Alzheimer's Disease Dementia
    Donepezil hydrochloride

    📚 Cited Papers (75)

    Effect of a cleavage-resistant collagen mutation on left ventricular remodeling.
    Circulation research (2003) · PMID:12855673
    1 figure
    Figures
    Figures
    Figures available at source paper (no open-access XML found).
    deep_link
    Gastrin-releasing peptide blockade as a broad-spectrum anti-inflammatory therapy for asthma.
    Proceedings of the National Academy of Sciences of the United States of America (2011) · PMID:21252304
    1 figure
    Figures
    Figures
    Figures available at source paper (no open-access XML found).
    deep_link
    Astrocytic LRP1 enables mitochondria transfer to neurons and mitigates brain ischemic stroke by suppressing ARF1 lactylation.
    Cell metabolism (2024) · PMID:38906140
    1 figure
    Figures
    Figures
    Figures available at source paper (no open-access XML found).
    deep_link
    Modulating LRP1 Pathways in Alzheimer's Disease: Mechanistic Insights and Emerging Therapies.
    Molecular neurobiology (2026) · PMID:41772271
    1 figure
    Figures
    Figures
    Figures available at source paper (no open-access XML found).
    deep_link
    Osteoclast-secreted galectin-3 promotes articular cartilage degeneration in OVX rats via LRP1/beta-catenin axis.
    Osteoarthritis Cartilage (2026) · PMID:40609733
    1 figure
    Figures
    Figures
    Figures available at source paper (no open-access XML found).
    deep_link
    Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR-ABCA1 signaling in Alzheimer's models.
    Neurotherapeutics (2026) · PMID:41934727
    1 figure
    Figures
    Figures
    Figures available at source paper (no open-access XML found).
    deep_link
    Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin.
    Nature genetics (2000) · PMID:10655062
    1 figure
    Figures
    Figures
    Figures available at source paper (no open-access XML found).
    deep_link
    Epidemiology of Barrett's esophagus and esophageal adenocarcinoma in Spain. A unicentric study.
    Revista espanola de enfermedades digestivas (2016) · PMID:27616661
    1 figure
    Figures
    Figures
    Figures available at source paper (no open-access XML found).
    deep_link
    Paper:10655062
    No extracted figures yet
    Paper:12855673
    No extracted figures yet
    Paper:17668063
    No extracted figures yet
    Paper:21252304
    No extracted figures yet

    📓 Linked Notebooks (1)

    📓 Tau propagation mechanisms and therapeutic interception points — Analysis Notebook
    CI-generated notebook stub for analysis SDA-2026-04-04-gap-tau-prop-20260402003221. Investigate prion-like spreading of tau pathology through connected brain regions, focusing on trans-synaptic transf …
    → Browse all notebooks

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    Wiki Pages

    LRP1 (Low-Density Lipoprotein Receptor-Related ProproteinLRP1 GenegeneTREM2 Agonist Therapies for Alzheimer's DiseasetherapeuticTau Immunotherapy for Alzheimer's DiseasetherapeuticSodium Oligomannate (GV-971) for Alzheimer's DiseatherapeuticSiponimod for Alzheimer's DiseasetherapeuticNanomedicine Approaches to Alzheimer's DiseasetherapeuticNanomedicine for Alzheimer's DiseasetherapeuticMemantine - NMDA Antagonist for Alzheimer's DiseastherapeuticKamuvudine-9: NRTI for Alzheimer's Disease NeurointherapeuticFerulic Acid Carbamate Derivatives for Alzheimer'stherapeuticDisease-Modifying Therapies for Alzheimer's DiseastherapeuticsCAR-T Cell Therapy for Alzheimer's DiseasetherapeuticCAR-A (Chimeric Antigen Receptor) Astrocyte TheraptherapeuticCAR-A Therapy - Chimeric Antigen Receptor Astrocyttreatment

    KG Entities (45)

    ADAM10AKTAPOEAPOE4APPAlzheimer's DiseaseAutophagy-lysosome pathwayCD33CHMP4BCX3CR1DAP12Endosomal sorting / vesicle traffickingExtracellular Vesicle Biogenesis ModulatHSP90HSP90-Tau Disaggregation Complex EnhanceHSP90AA1LAMP1LAMP2LC3LRP1

    Dependency Graph (2 upstream, 3 downstream)

    Depends On
    Tau-Independent Microtubule Stabilization via MAP6 Enhancementbuilds_on (1.0)Noradrenergic-Tau Propagation Blockadebuilds_on (1.0)
    Depended On By
    HSP90-Tau Disaggregation Complex Enhancementbuilds_on (1.0)Synaptic Vesicle Tau Capture Inhibitionbuilds_on (1.0)TREM2-mediated microglial tau clearance enhancementbuilds_on (1.0)

    Linked Experiments (10)

    Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy in 4R-Tauopathyvalidation | tests | 0.46Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauopathyclinical | tests | 0.46Tau Spreading Network Mapping via Spatial Transcriptomics in PSPclinical | tests | 0.464R-Tau Targeting Therapies for PSP and CBSclinical | tests | 0.46Tau Propagation Causality Test — Does Tau Spread Drive Neurodegeneration or Is Iclinical | tests | 0.46CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omics Studyvalidation | tests | 0.46Tau Pathology Initiation Zone Identificationclinical | tests | 0.46PSP and CBS Biomarker Validation Studyclinical | tests | 0.46Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have Not Succeedclinical | tests | 0.46Blood Biomarker vs Tau PET for Treatment Monitoringclinical | tests | 0.46

    Related Hypotheses

    ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia
    Score: 0.662 | Alzheimer's Disease
    Cell-Type Specific TREM2 Upregulation in DAM Microglia
    Score: 0.519 | Alzheimer's Disease
    GFAP-Positive Reactive Astrocyte Subtype Delineation
    Score: 0.518 | Alzheimer's Disease
    40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively Eliminate Disease-Associated Microglia
    Score: 0.515 | Alzheimer's Disease
    ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matter Degeneration in Alzheimer's Disease
    Score: 0.512 | Alzheimer's Disease

    Estimated Development

    Estimated Cost
    $2M
    Timeline
    2.3 years

    🧪 Falsifiable Predictions (1)

    1 total 0 confirmed 0 falsified
    Test prediction
    pending conf: 0.70
    Expected outcome: Test outcome
    Falsified by: If test fails

    Knowledge Subgraph (100 edges)

    associated with (8)

    CHMP4B neurodegeneration
    CHMP4B Alzheimer's Disease
    VCP Alzheimer's Disease
    HSP90AA1 Alzheimer's Disease
    SNAP25 Alzheimer's Disease
    ...and 3 more

    co associated with (22)

    HSP90AA1 HSP90
    CHMP4B SNAP25
    CHMP4B TREM2
    CHMP4B NLGN1
    HSP90AA1 VCP
    ...and 17 more

    co discussed (39)

    SORL1 TAU
    AKT DAP12
    APOE DAP12
    DAP12 PI3K
    DAP12 TFEB
    ...and 34 more

    implicated in (4)

    CHMP4B neurodegeneration
    VCP neurodegeneration
    SNAP25 neurodegeneration
    NLGN1 neurodegeneration

    involved in (1)

    TREM2 trem2_dap12_microglial_signaling

    participates in (5)

    CHMP4B Endosomal sorting / vesicle trafficking
    VCP Autophagy-lysosome pathway
    HSP90AA1 Tau protein / microtubule-associated pathway
    SNAP25 Tau protein / microtubule-associated pathway
    NLGN1 Synaptic function / plasticity

    regulates (14)

    LRP1 LRP1-Dependent Tau Uptake Disruption
    LRP1 Tau Propagation
    TREM2 TREM2-mediated microglial tau clearance enhancemen
    TREM2 Tau Propagation
    CHMP4B Extracellular Vesicle Biogenesis Modulation
    ...and 9 more

    therapeutic target (7)

    LRP1-Dependent Tau Uptake Disruption Alzheimer's Disease
    TREM2-mediated microglial tau clearance enhancemen Alzheimer's Disease
    Extracellular Vesicle Biogenesis Modulation Alzheimer's Disease
    VCP-Mediated Autophagy Enhancement Alzheimer's Disease
    HSP90-Tau Disaggregation Complex Enhancement Alzheimer's Disease
    ...and 2 more

    Mechanism Pathway for LRP1

    Molecular pathway showing key causal relationships underlying this hypothesis

    graph TD
        LRP1["LRP1"] -->|regulates| LRP1_Dependent_Tau_Uptake["LRP1-Dependent Tau Uptake Disruption"]
        LRP1_Dependent_Tau_Uptake_1["LRP1-Dependent Tau Uptake Disruption"] -->|therapeutic target| Alzheimer_s_Disease["Alzheimer's Disease"]
        LRP1_2["LRP1"] -->|regulates| Tau_Propagation["Tau Propagation"]
        HSP90AA1["HSP90AA1"] -->|co associated with| LRP1_3["LRP1"]
        CHMP4B["CHMP4B"] -->|co associated with| LRP1_4["LRP1"]
        LRP1_5["LRP1"] -->|co associated with| SNAP25["SNAP25"]
        LRP1_6["LRP1"] -->|co associated with| TREM2["TREM2"]
        LRP1_7["LRP1"] -->|co associated with| NLGN1["NLGN1"]
        LRP1_8["LRP1"] -->|co associated with| VCP["VCP"]
        style LRP1 fill:#ce93d8,stroke:#333,color:#000
        style LRP1_Dependent_Tau_Uptake fill:#4fc3f7,stroke:#333,color:#000
        style LRP1_Dependent_Tau_Uptake_1 fill:#4fc3f7,stroke:#333,color:#000
        style Alzheimer_s_Disease fill:#ef5350,stroke:#333,color:#000
        style LRP1_2 fill:#ce93d8,stroke:#333,color:#000
        style Tau_Propagation fill:#ffd54f,stroke:#333,color:#000
        style HSP90AA1 fill:#ce93d8,stroke:#333,color:#000
        style LRP1_3 fill:#ce93d8,stroke:#333,color:#000
        style CHMP4B fill:#ce93d8,stroke:#333,color:#000
        style LRP1_4 fill:#ce93d8,stroke:#333,color:#000
        style LRP1_5 fill:#ce93d8,stroke:#333,color:#000
        style SNAP25 fill:#ce93d8,stroke:#333,color:#000
        style LRP1_6 fill:#ce93d8,stroke:#333,color:#000
        style TREM2 fill:#ce93d8,stroke:#333,color:#000
        style LRP1_7 fill:#ce93d8,stroke:#333,color:#000
        style NLGN1 fill:#ce93d8,stroke:#333,color:#000
        style LRP1_8 fill:#ce93d8,stroke:#333,color:#000
        style VCP fill:#ce93d8,stroke:#333,color:#000

    3D Protein Structure

    🧬 LRP1 — PDB 1CR8 Click to expand 3D viewer

    Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

    Source Analysis

    Tau propagation mechanisms and therapeutic interception points

    neurodegeneration | 2026-04-04 | completed